Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Chiriax; MF-934; Monos; Qari; Rufakin; Tebraxin

Latest Information Update: 10 Jul 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mediolanum
  • Developer Bracco; Hilton Pharma; Laboratoires Leurquin-Mediolanum; Selvi Laboratorio Bioterapico; Universal Pharma Holdings
  • Class Antibacterials; Fluoroquinolones; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bacterial infections; Respiratory tract infections; Urinary tract infections

Most Recent Events

  • 10 Jul 2007 Discontinued - Phase-III for Bacterial infections in United Kingdom (PO)
  • 10 Jul 2007 Discontinued - Phase-III for Bacterial infections in USA (PO)
  • 06 Dec 2001 Registered for Bacterial infections in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top